Replies to post #236238 on Innovation Pharmaceuticals Inc (IPIX)

[Empiricst1]

Yes, as a monotherapy, or possibly as adjuvant therapy.

[petemantx]

And one can't forget that P2b trials are always set up by the company to highlight the strengths of the drug as evidenced in the P2a. In Prurisol's case, this meant that we went to the PASI scale for measurement of improvement, trial patients were all moderate to severe cases instead of mild to moderate, and there were stringent criteria regarding prior treatments using other drugs to get into the trial. All should bode well for P2b results.

Lots going for Prurisol in P2b, can't really see any glaring shortcomings that should cause worry regarding the results.